TheTechno Optimist.

PEARL TrialAgelessRx—AgelessRx wins $1M XPRIZE Healthspan Milestone 2 award for expanded clinical trialAgelessRx—AgelessRx makes 2026 Inc. 5000 list of fastest-growing private companies for second consecutive year

PEARL Trial

by AgelessRxUS

48-week RCT testing weekly low-dose rapamycin (5–10 mg) in 114 adults (50–85 yrs). Primary: visceral fat; secondary: muscle, blood markers, quality of life.

DeployStage 4 of 5

PEARL: 48-week trial with 114 adults completed, results published. XPRIZE trial ongoing 2026–2029.

Updated 11 Aug 2026Checked 10 Oct0 updates this week

Milestones

Next · XPRIZE trial: muscle, cognitive, immune endpoints (~186 adults)
  1. PEARL trial enrollment begins2024Complete.
  2. 48-week primary outcomes analysis complete2025Complete.
  3. Results published in Aging (Aging-US)Apr 2025Complete.
  4. XPRIZE Healthspan Milestone 2 award ($1M)Aug 2026Complete.
  5. XPRIZE trial: muscle, cognitive, immune endpoints (~186 adults)Target 2026Current milestone.
  6. XPRIZE trial completion with final readoutTarget 2029Not yet reached.

Most important updates

Upcoming

  1. 2026XPRIZE trial: muscle, cognitive, immune endpoints (~186 adults) (next)
  2. 2027XPRIZE Healthspan trial full enrollment and 2027 interim readout
  3. 2029XPRIZE trial completion with final readout
  4. 2029Publication of XPRIZE Healthspan results
Primer